



ATTORNEY'S DOCKET NO: M1015/7013 TJO/TC

AUG 2 1 2001

TECH CENTER 1600/2900

Applicant:

Serial No:

Filed:

For:

Cynthia C. Bamdad
09/631,818
August 3, 2000
RAPID AND SENSITIVE DETECTION OF PROTEIN AGGREGATION
Not Vet Assigned

Examiner:

Art Unit:

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on August 13, 2001.

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith is/are the following document(s):

- Preliminary Amendment [X]
- Return Receipt Postcard [X]

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is due. If the fee is insufficient, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

Timothy J. Oyef, Reg. No. 36,628 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Tel. No.: (617) 720-3500

Docket No.: M1015/7013 Date: August 13, 2001



RECEIVED

ATTORNEY'S DOCKET NO: M1015/7013 TJO/TC

AUG 2 1 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTER 1600/2900

Applicant:

Cynthia C. Bamdad

Serial No:

09/631,818

Filed:

August 3, 2000

For:

RAPID AND SENSITIVE DETECTION OF PROTEIN AGGREGATION

Examiner:

Not Yet Assigned

Art Unit:

1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on August 13, 2001.

Commissioner for Patents Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

AECEIVED
TC 1700 Before beginning examination of the above-identified application on its merits, please amend the application as follows:

In the Claims:

Please rewrite the claims below as shown. A marked-up version of the rewritten claims is appended hereto illustrating these changes.

A method as in claim \$16, wherein each of the first and second chemical or 318. biological species is derived from vittorectin, and the third chemical or biological species is endostatin.

319. A method as in claim 317, wherein each of the first and second chemical or biological species is vitronectin, the third chemical or biological species is endostatin, and the candidate drug is a candidate for disruption of vitronectin/endostatin binding.